Detalhe da pesquisa
1.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
N Engl J Med
; 388(19): 1767-1778, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163623
2.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34125340
3.
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
JAMA
; 317(1): 37-47, 2017 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27918780
4.
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
BioDrugs
; 36(6): 749-760, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169807
5.
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.
Clin Lymphoma Myeloma Leuk
; 22(2): 89-97, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34686445
6.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
BioDrugs
; 35(4): 429-444, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914256
7.
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Breast
; 58: 18-26, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33892316
8.
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Cancer Treat Rev
; 66: 104-113, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29730461
9.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Lancet Haematol
; 5(11): e543-e553, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30389036